...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Antimicrobial agents and chemotherapy. >Reduction in fluoroquinolone use following introduction of ertapenem into a hospital formulary is associated with improvement in susceptibility of Pseudomonas aeruginosa to group 2 carbapenems: a 10-year study.
【24h】

Reduction in fluoroquinolone use following introduction of ertapenem into a hospital formulary is associated with improvement in susceptibility of Pseudomonas aeruginosa to group 2 carbapenems: a 10-year study.

机译：将厄他培南引入医院处方后减少氟喹诺酮的使用与铜绿假单胞菌对第2组碳青霉烯类药物的敏感性改善有关：一项为期10年的研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We examined the effect of the addition of ertapenem to our hospital formulary on the resistance of nosocomial Pseudomonas aeruginosa to group 2 carbapenems (imipenem, meropenem, and doripenem). This was a retrospective, observational study conducted between 1 January 2000 and 31 January 2009 at a large, tertiary-care hospital. Autoregressive integrated moving average (ARIMA) regression models were used to evaluate the effect of ertapenem use on the susceptibility of Pseudomonas aeruginosa to group 2 carbapenems as well as on the use of the group 2 carbapenems, ciprofloxacin, and other antipseudomonal drugs (i.e., tobramycin, cefepime, and piperacillin-tazobactam). Resistance was expressed as a percentage of total isolates as well as the number of carbapenem-resistant bacterial isolates per 10,000 patient days. Pearson correlation was used to assess the relationship between antibiotic use and carbapenem resistance. Following the addition of ertapenem to the formulary, there was a statistically significant decrease in the percentage of Pseudomonas aeruginosa isolates resistant to the group 2 carbapenems (P = 0.003). Group 2 carbapenem use and the number of carbapenem-resistant Pseudomonas aeruginosa isolates per 10,000 patient days did not change significantly over the time period. There was a large decrease in the use of ciprofloxacin (P = 0.0033), and there was a correlation of ciprofloxacin use with the percentage of isolates resistant to the group 2 carbapenems (rho = 0.47, P = 0.002). We suspect that the improvement in susceptibility of Pseudomonas aeruginosa to group 2 carbapenems was related to a decrease in ciprofloxacin use.
机译：我们研究了在我们的医院处方中添加厄他培南对铜绿假单胞菌对第2组碳青霉烯类（亚胺培南，美罗培南和多立培南）的耐药性的影响。这是一项于2000年1月1日至2009年1月31日期间在一家大型三级护理医院进行的回顾性观察研究。自回归综合移动平均值（ARIMA）回归模型用于评估使用ertapenem对铜绿假单胞菌对第2组碳青霉烯类药物的敏感性以及对第2组碳青霉烯类，环丙沙星和其他抗假性伪狂犬病药物（即妥布霉素）的影响，头孢吡肟和哌拉西林-他唑巴坦）。耐药性表示为总分离株的百分比以及每10,000个病人日对碳青霉烯耐药的细菌分离株的数量。皮尔逊相关性用于评估抗生素使用与碳青霉烯耐药性之间的关系。在将厄他培南添加到配方中后，对第2组碳青霉烯类耐药的铜绿假单胞菌分离物的百分比在统计学上显着降低（P = 0.003）。第2组碳青霉烯的使用以及每10,000患者日对碳青霉烯耐药的铜绿假单胞菌分离株的数量在这段时间内没有显着变化。环丙沙星的使用大幅减少（P = 0.0033），并且环丙沙星的使用与对第2组碳青霉烯类耐药的分离株的百分比相关（rho = 0.47，P = 0.002）。我们怀疑铜绿假单胞菌对第2组碳青霉烯类药物的敏感性改善与环丙沙星使用量减少有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号